All Stories

  1. Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy
  2. Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)
  3. Autonomic dysfunction and risk of severe hypoglycemia among individuals with type 2 diabetes
  4. Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study
  5. Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry
  6. Evaluation of Clinical Metrics for Identifying Defective Physiologic Responses to Hypoglycemia in Long-Standing Type 1 Diabetes
  7. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes
  8. Characterizing Glycemic Control and Sleep in Adults with Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery
  9. Pancreatic islet reserve in type 1 diabetes
  10. A tale of two pancreases: exocrine pathology and endocrine dysfunction
  11. High residual C-peptide likely contributes to glycemic control in type 1 diabetes
  12. Different β‐cell secretory phenotype in non‐obese compared to obese early type 2 diabetes
  13. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries
  14. The Transatlantic HbA 1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry
  15. Advances in β-cell replacement therapy for the treatment of type 1 diabetes
  16. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
  17. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia
  18. Cognitions Associated With Hypoglycemia Awareness Status and Severe Hypoglycemia Experience in Adults With Type 1 Diabetes
  19. Hypoglycemia‐associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes
  20. Stem Cell–Derived Islets: Next Steps for Histologic and Functional Assessment During Development as a Cellular Therapy for the Treatment of Diabetes
  21. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation
  22. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
  23. Cheiroarthropathy: A Common Disorder in Patients in the T1D Exchange
  24. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
  25. Successful pregnancies after islet transplantation for type 1 diabetes
  26. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
  27. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study
  28. Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry
  29. Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer
  30. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes
  31. Metabolic network reconstruction and phenome analysis of the industrial microbe, Escherichia coli BL21(DE3)
  32. Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes
  33. Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells
  34. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia
  35. Effects of GLP-1 and GIP on Insulin Secretion in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis
  36. Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network
  37. Risk Factors for Adverse Kidney Disease Outcomes in Type 1 Diabetes (T1D)
  38. β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL
  39. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes
  40. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop
  41. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study (Preprint)
  42. Defining outcomes for beta cell replacement therapy: a work in progress
  43. Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial
  44. A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors
  45. Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long Standing Type 1 Diabetes
  46. Dose–response effects of exercise on insulin among colon cancer survivors
  47. Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes
  48. Dose–response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial
  49. Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels
  50. Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults with Type 1 Diabetes
  51. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer
  52. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue
  53. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes
  54. Centennial Celebration: Endocrine Reviews Past Highlights for November and December
  55. Autoimmune Diseases in Children and Adults With Type 1 Diabetes From the T1D Exchange Clinic Registry
  56. Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes
  57. Physiology-Invariant Meal Detection for Type 1 Diabetes
  58. Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264–270
  59. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance
  60. Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement
  61. Selective association of electrocardiographic abnormalities with insulin sensitivity and beta-cell function in type 2 diabetes mellitus: a cross-sectional analysis
  62. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
  63. A randomized phase II dose–response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results
  64. Pancreas Transplantation in the Modern Era
  65. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
  66. Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
  67. Vascular Health Profile predicts cardiovascular outcomes in patients with diabetes
  68. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
  69. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes
  70. A Data-Driven Behavior Modeling and Analysis Framework for Diabetic Patients on Insulin Pumps
  71. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics
  72. A Role for Transplant Endocrinologists - It's About Time
  73. Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia
  74. Activation of Innate Immunity Modulates Insulin Sensitivity, Glucose Effectiveness and Pancreatic β-Cell Function in Both African Ancestry and European Ancestry Healthy Humans
  75. Consistency of Quantitative Scores of Hypoglycemia Severity and Glycemic Lability and Comparison with Continuous Glucose Monitoring System Measures in Long-Standing Type 1 Diabetes
  76. Total Pancreatectomy With Islet Autotransplantation
  77. Restoration of Glucose Counterregulation by Islet Transplantation in Long-standing Type 1 Diabetes
  78. Islet Product Characteristics and Factors Related to Successful Human Islet Transplantation From the Collaborative Islet Transplant Registry (CITR) 1999–2010
  79. Total Pancreatectomy With Islet Autotransplantation
  80. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides
  81. GLP-1 Plays a Limited Role in Improved Glycemia Shortly After Roux-en-Y Gastric Bypass: A Comparison With Intensive Lifestyle Modification
  82. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults
  83. Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
  84. Mutations in abca1 are associated with enhanced beta-cell secretory capacity in humans
  85. Insulin sensitivity index in type 1 diabetes and following human islet transplantation: comparison of the minimal model to euglycemic clamp measures
  86. Completion of the first FDA phase 3 multicenter trial of Islet transplantation in type 1 diabetes by the NIH CIT consortium
  87. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: Recommendations from PancreasFest
  88. Differential Associations of Oral Glucose Tolerance Test–Derived Measures of Insulin Sensitivity and Pancreatic β-Cell Function With Coronary Artery Calcification and Microalbuminuria in Type 2 Diabetes
  89. Improvement in Insulin Sensitivity After Human Islet Transplantation for Type 1 Diabetes
  90. Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
  91. Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry
  92. Improvement in β-Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol
  93. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012
  94. Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus
  95. Case 33-2012: A Woman with Altered Mental Status after Childbirth
  96. Severe Insulin Resistance and Hypertriglyceridemia After Childhood Total Body Irradiation
  97. Raising Serum Gastrin to Improve Glycemic Control in (Type 2) Diabetes: Another Limb of the Enteroinsular Axis?
  98. Long Term Outcomes of Allogeneic Islet Transplantation: The Collaborative Islet Transplant Registry (CITR) 1999-2010
  99. Recovery of Endocrine Function After Islet and Pancreas Transplantation
  100. A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial
  101. Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010
  102. Metabolic Function of a Suboptimal Transplanted Islet Mass in Nonhuman Primates on Rapamycin Monotherapy
  103. Early Metabolic Markers That Anticipate Loss of Insulin Independence in Type 1 Diabetic Islet Allograft Recipients
  104. HLA Class I Sensitization in Islet Transplant Recipients: Report from the Collaborative Islet Transplant Registry
  105. Accumulation of Intrahepatic Islet Amyloid in a Nonhuman Primate Transplant Model
  106. Hypersensitivity to Rabbit Antithymocyte Globulin in an Islet Transplant Recipient: A Case Report
  107. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose
  108. Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation
  109. Amelioration of Hypoglycemia With Octreotide Therapy in Metastatic Insulinoma With Positive Octreotide Scan
  110. Analysis of B cell subsets following pancreatic islet cell transplantation in a patient with type 1 diabetes by cytometric fingerprinting
  111. Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial
  112. Fatal Malnutrition 6 Years After Gastric Bypass Surgery
  113. Proinsulin Processing and Transplanted Islets
  114. β-Cell Secretory Capacity and Demand in Recipients of Islet, Pancreas, and Kidney Transplants
  115. Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans
  116. Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus
  117. Exenatide Use in Islet Transplantation: Words of Caution
  118. Effect of Glucagon-Like Peptide-1 on β- and α-Cell Function in Isolated Islet and Whole Pancreas Transplant Recipients
  119. Amyloid and Transplanted Islets
  120. RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes
  121. Insulin Sensitivity, Food Intake, and Cravings with Premenstrual Syndrome: A Pilot Study
  122. Acute Insulin Responses to Glucose and Arginine as Predictors of β-Cell Secretory Capacity in Human Islet Transplantation
  123. Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on β-Cell Secretory Capacity
  124. Innate Immunity Modulates Adipokines in Humans
  125. Menstrual Cycle Effects on Insulin Sensitivity in Women with Type 1 Diabetes: A Pilot Study
  126. Glycemic Thresholds for Activation of Counterregulatory Hormone and Symptom Responses in Islet Transplant Recipients
  127. Calcific Uremic Arteriolopathy (Calciphylaxis)
  128. Insulin Sensitivity, Glucose Effectiveness, and Free Fatty Acid Dynamics after Human Islet Transplantation for Type 1 Diabetes
  129. Islet Cell Hormonal Responses to Hypoglycemia After Human Islet Transplantation for Type 1 Diabetes
  130. Impaired β-Cell Function in Type 1 Diabetes after Islet Transplantation
  131. Hypocalciuric Hypercalcemia and Autoantibodies against the Calcium-Sensing Receptor
  132. Hyperfunctioning Intrathyroidal Parathyroid Cyst
  133. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants